companydata.dkLIPLASOME PHARMA ApS: Financial statements 2018
CVR: 29428514
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -61,000 and a net result of DKK -54,000 compared with DKK -55,000 the year before. Equity amounted to DKK 33,784,000. The solvency ratio was 88.3%.
- Gross Profit
- -61,000 kr.
- Profit/Loss
- -54,000 kr.
- Equity
- 33,784,000 kr.
- Total Assets
- 38,273,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -61 t. | -54 t. | 33.8 mio. | - |
| 2017 | - | -65 t. | -55 t. | 33.8 mio. | 0 |
| 2016 | - | -328 t. | -309 t. | 33.9 mio. | 0 |
| 2015 | - | -1.7 mio. | -2.5 mio. | 34.2 mio. | 2 |
| 2014 | - | -1.5 mio. | -2.4 mio. | 31.8 mio. | 2 |
Keep an eye on LIPLASOME PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2018
LIPLASOME PHARMA ApS has published its annual report for 2017. Gross profit came to DKK -65,000, and the net result was DKK -55,000.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hans-Henrik Horsted Eriksen. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity amounted to DKK 2,377,000.